HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the... |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
bortezomib injection 3.5 MG VIAL (bortezomib for injection)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
bortezomib injection 3.5 MG VIAL Quick Finder
1 INDICATIONS AND USAGE
1.1 Multiple Myeloma
Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma.
2 DOSAGE AND ADMINISTRATION
2.1 Important Dosing Guidelines
Bortezomib for injection is for intravenous or subcutaneous use only. Do not administer bortezomib for...
3 DOSAGE FORMS AND STRENGTHS
For injection: Each single-dose vial of bortezomib for injection contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder for reconstitution and withdrawal of the...
4 CONTRAINDICATIONS
Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [...
5 WARNINGS AND PRECAUTIONS
5.1 Peripheral Neuropathy
Bortezomib for injection treatment causes a peripheral neuropathy that is predominantly sensory; however, cases...
7 DRUG INTERACTIONS
7.1 Effects of Other Drugs on Bortezomib for Injection
Strong CYP3A4...
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on its mechanism...
10 OVERDOSAGE
There is no known specific antidote for bortezomib for injection overdosage. In humans, fatal outcomes following the administration of more than twice the recommended therapeutic dose have been reported, which...
11 DESCRIPTION
Bortezomib for Injection, a proteasome inhibitor, is an antineoplastic agent. Bortezomib is a modified dipeptidyl boronic acid. The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1...
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The...
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies have not been conducted with bortezomib.
Bortezomib...
14 CLINICAL STUDIES
14.1 Multiple Myeloma
Randomized, Open-Label Clinical Study in Patients...
15 REFERENCES
- "OSHA Hazardous Drugs" (refer to antineoplastic weblinks including OSHA Technical Manual). OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html...
16 HOW SUPPLIED/STORAGE AND HANDLING
Bortezomib for Injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder.
17 PATIENT COUNSELING INFORMATION
Discuss the following with patients prior to treatment with bortezomib for injection:
Peripheral...
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.